不同剂量阿托伐他汀对冠心病性心力衰竭患者血浆超敏C反应蛋白、N末端脑利钠肽前体水平影响

目的观察阿托伐他汀对冠心病心力衰竭患者心功能及血浆超敏C反应蛋白(hs-CRP)及N末端脑利钠肽前体(NT-pro BNP)水平影响。方法选择本院于2013年6月至2013年12月收治的冠心病心力衰竭患者68例作为研究对象,随机分为两组,每组34例,两组均给予纠正心衰药物治疗,对照组给予阿托伐他汀治疗,剂量10 mg,观察组给予20 mg阿托伐他汀治疗,1次/d,连续12周,比较两组患者心功能及血浆hs-CRP及NT-pro BNP水平变化。结果观察组心功能改善总有效率33例(97.1%),明显高于对照组27例(79.4%),χ2=5.100,P<0.05。观察组hs-CRP、NT-pro BNP水平分别为(1.1±0.2)mg/L、(312.3±45.2)ng/ml,均低于对照组的(1.8±0.4)mg/L、(389.4±52.3)ng/ml,P<0.05。观察组左心室射血分数(LVEF)、二尖瓣口舒张早期最大流速与舒张末期最大流速比率(E/A)分别为(45±1)%、1.32±0.04,均高于对照组的(41±2)%、1.09±0.05,P<0.05。结论阿托伐他汀可有效改善冠心病心力衰竭患者心功能,并具有降低血浆hs-CRP及NT-pro BNP水平作用,具有重要临床价值。

Effect of atorvastatin on plasma high sensitivity C reactive protein,N terminal pro-B-type natriuretic peptide level of coronary heart disease patients with heart failure

ObjectiveTo investigate the effect of atorvastatin on heart function and plasma high sensitivity C reactive protein （hs-CRP） and N terminal pro brain natriuretic peptide （NT-proBNP） levels in coronary heart disease patients with heart failure.Methods 68 patients treated in the hospital in 2013 June-2013 year in December admitted to the coronary heart failure were selected as the research objects, all randomly were divided into two groups with 34 cases in each group, all patients were given correct drug treatment for heart failure, the control group adopted treatment of atorvastatin with dose of 10 mg, and observation group adopted 20 mg atorvastatin, once a day, 12 consecutive weeks, to compare changes between two groups of patients with cardiac function and plasma hs-CRP and NT-proBNP levels. ResultsThe total efficiency of heart function improved in the observation group was 33 cases （97.1%） and significantly higher than that of the control group of 27 cases （79.4%）,χ2=5.100,P〈0.05. The level of NT-proBNP, hs-CRP in the observation group respectively were （1.1±0.2）mg/L, （312.3±45.2）ng/ml and were lower than the control group’ （1.8±0.4）mg/L, （389.4±52.3）ng/ml,P〈0.05. Left ventricular ejection fraction （LVEE） and mitral early diastolic peak velocity and diastolic peak velocity ratio （E/A） in the observation group were （45±1）%, 1.32±0.04 and were higher than the control group’ （41±2）%,1.09±0.05, P〈0.05.Conclusion Atorvastatin can effectively improve heart function of coronary heart disease in patients with heart failure and can reduce the plasma level of hs-CRP and NT-proBNP, so it has important clinical value.